Antengene Wins Hong Kong Approval for XPOVIO in Multiple Myeloma and Lymphoma
Antengene Corporation Limited has received approval from the Hong Kong Department of Health for two supplemental New Drug Applications for XPOVIO®. The approvals include its use in combination with other drugs for multiple myeloma and as a monotherapy for diffuse large B-cell lymphoma. This marks a significant regulatory milestone for Antengene in expanding the use of XPOVIO® in Hong Kong.
Antengene Corporation Limited announced that the Department of Health of the Hong Kong Special Administrative Region has approved two supplemental New Drug Applications for XPOVIO® (selinexor). The approvals cover XPOVIO® in combination with bortezomib and dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy, and XPOVIO® as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for haematopoietic cell transplant after at least two lines of systemic therapy. No other organizations were mentioned as obtaining this approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251203-11941347), on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
